Cutia Therapeutics (SEHK:2487) Margins Stay Deep In The Red Challenging Profitability Narrative

Cutia Therapeutics (SEHK:2487) opened FY 2025 with first half revenue of C¥66.3 million and a basic EPS loss of C¥0.75, while trailing twelve month revenue sat at C¥336.2 million against a basic EPS loss of C¥1.03. The company reported revenue of C¥95.6 million in the first half of 2024, C¥184.0 million in the second half of 2024, and C¥66.3 million in the first half of 2025, with basic EPS losses of C¥0.66, C¥0.75 and C¥0.75 over those same periods. This sequence highlights that investors are still watching for the inflection point in margins.

See our full analysis for Cutia Therapeutics.

With the headline numbers in place, the next step is to see how this earnings print lines up with the key narratives around growth, profitability and risk that have been building around Cutia Therapeutics over the last year.

Curious how numbers become stories that shape markets? Explore Community Narratives

TTM loss of C¥340.2 million keeps margins in the red

• Over the trailing twelve months, Cutia booked C¥336.2 million in revenue against a net income loss of C¥340.2 million, so the business is still operating with a negative net margin on a full year look.
• What stands out for the bullish narrative that focuses on an 89.14% forecast earnings growth rate is that trailing losses remain sizable, with C¥239.4 million of net income loss in 1H FY 2025 and C¥232.9 million in 2H FY 2024. This means any thesis built around future profitability needs to account for how far current margins still are from break even.

LTM EPS loss of C¥1.03 vs five year loss reduction story

• The latest trailing twelve month basic EPS loss is C¥1.03, compared with semi annual basic EPS losses of C¥0.66 in 1H 2024, C¥0.75 in 2H 2024 and C¥0.75 in 1H 2025. Per share results have therefore stayed in loss making territory even as longer term data points to a 23.3% annual reduction in losses over five years.
• Analysts who highlight that losses have been reduced by about 23.3% per year over five years have that bullish argument tested by the recent sequence, where basic EPS loss of C¥0.66 in 1H 2024 widened to C¥0.75 in both 2H 2024 and 1H 2025, and net income loss moved from C¥200.9 million in 1H 2024 to C¥232.9 million in 2H 2024 and C¥239.4 million in 1H 2025. The long term trend of improvement has not yet translated into a clear step toward profitability in the most recent halves.

Stay on top of how different investors are interpreting these loss trends and revenue figures by checking the range of community views on Cutia Therapeutics through the Curious how numbers become stories that shape markets? Explore Community Narratives.

Valuation gap vs DCF fair value and P/S peers

• At a current share price of HK$4.78, the stock is described as trading below a DCF fair value of about HK$17.96 and on a P/S multiple of 4.6x compared with 12.7x for the Hong Kong Biotechs industry and 13.8x for peers. Both the discounted cash flow comparison and sales based multiples point to a lower valuation versus those reference points.
• Bears who focus on the current lack of profitability and negative trailing net margin still need to weigh that concern against several reward signals, including the cited 30.8% revenue growth forecast compared with an 8.2% Hong Kong market forecast, the expectation of 89.14% annual earnings growth with a path to profitability within three years, and the 73.4% gap between the HK$4.78 share price and the HK$17.96 DCF fair value. Together, these factors frame a tension between current loss making status and the valuation metrics that reference stronger future performance.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Cutia Therapeutics's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

With mixed signals around losses, revenue and valuation in mind, it helps to look at the underlying data yourself and decide how compelling the story feels. To see exactly what rewards others are optimistic about, and to pressure test your own view, check the 4 key rewards.

Explore Alternatives

Cutia Therapeutics is still recording sizable losses, with trailing twelve month net income of C¥340.2 million in the red and no clear move toward break even in the latest halves.

If you want ideas that do not carry the same pressure of ongoing losses, start by checking 289 resilient stocks with low risk scores to quickly spot companies with more resilient profiles.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com